ly3009120 and Thyroid-Neoplasms

ly3009120 has been researched along with Thyroid-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for ly3009120 and Thyroid-Neoplasms

Article	Year
Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer. Theranostics, 2017, Volume: 7, Issue:4 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Resistance; Enzyme Inhibitors; Heterografts; Humans; Indoles; Mice, Nude; Phenylurea Compounds; Protein Multimerization; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrimidines; Pyrroles; Sulfonamides; Thyroid Neoplasms; Treatment Outcome; Vemurafenib	2017

Article

Year

Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer.

Theranostics, 2017, Volume: 7, Issue:4

Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Resistance; Enzyme Inhibitors; Heterografts; Humans; Indoles; Mice, Nude; Phenylurea Compounds; Protein Multimerization; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrimidines; Pyrroles; Sulfonamides; Thyroid Neoplasms; Treatment Outcome; Vemurafenib

2017